Pfizer Inc. $PFE Shares Sold by Sector Gamma AS

Sector Gamma AS cut its position in Pfizer Inc. (NYSE:PFE) by 31.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 859,539 shares of the biopharmaceutical company’s stock after selling 392,547 shares during the quarter. Pfizer accounts for about 4.9% of Sector Gamma AS’s portfolio, making the stock its 7th largest holding. Sector Gamma AS’s holdings in Pfizer were worth $21,403,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in PFE. Norges Bank acquired a new position in shares of Pfizer in the 4th quarter valued at approximately $1,830,986,000. Bank of New York Mellon Corp raised its position in shares of Pfizer by 38.9% in the 4th quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company’s stock valued at $1,208,023,000 after buying an additional 13,581,757 shares in the last quarter. Franklin Resources Inc. raised its position in shares of Pfizer by 47.8% in the 3rd quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock valued at $638,787,000 after buying an additional 8,108,887 shares in the last quarter. Capital World Investors raised its position in shares of Pfizer by 51.5% in the 4th quarter. Capital World Investors now owns 21,433,890 shares of the biopharmaceutical company’s stock valued at $533,704,000 after buying an additional 7,287,194 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Pfizer by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock valued at $13,479,520,000 after buying an additional 7,031,162 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer said the U.S. FDA expanded the label for HYMPAVZI to include more hemophilia A and B patients, including children ages 6-11 and patients with inhibitors, which could broaden sales potential in a high-value rare disease market. Article Title
• Positive Sentiment: RBC Capital upgraded Pfizer to Sector Perform from Underperform, saying the stock’s valuation has reset and the risk/reward looks more balanced ahead of key pipeline catalysts. Article Title
• Positive Sentiment: Pfizer also highlighted ongoing clinical progress, including updates to trials for its next-gen pneumococcal shot, obesity candidate SOLIS-1, and early-stage research, reinforcing investor hopes that the pipeline can offset future patent and COVID-related revenue pressure. Article Title
• Neutral Sentiment: Several brokerages now rate Pfizer around Hold, suggesting the market sees limited near-term upside until more proof emerges from the pipeline and growth strategy. Article Title
• Negative Sentiment: One article warned that Pfizer’s rich dividend yield may reflect cash-flow and debt concerns, while another noted CEO Albert Bourla is reconsidering Germany investments because of drug-pricing policy risks, both of which could weigh on sentiment. Article Title

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on PFE shares. Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Barclays started coverage on shares of Pfizer in a research report on Thursday, February 19th. They set an “underweight” rating and a $25.00 price objective for the company. Daiwa Securities Group cut shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective for the company. in a research report on Thursday, February 12th. Royal Bank Of Canada upgraded shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective for the company in a research report on Tuesday. Finally, CICC Research started coverage on shares of Pfizer in a research report on Thursday, April 16th. They set an “outperform” rating and a $33.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and a consensus target price of $28.82.

Pfizer Trading Up 2.2%

PFE opened at $26.17 on Friday. Pfizer Inc. has a fifty-two week low of $23.11 and a fifty-two week high of $28.75. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The firm has a market capitalization of $149.15 billion, a price-to-earnings ratio of 19.98 and a beta of 0.34. The company’s 50 day moving average price is $26.48 and its two-hundred day moving average price is $26.32.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The company had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The company’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, research analysts predict that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, May 8th. This represents a $1.72 annualized dividend and a yield of 6.6%. Pfizer’s dividend payout ratio is presently 131.30%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.